Ligand Pharmaceuticals Incorporated (LGND)

72.83 -1.07 (-1.45%) 收市：04:00PM EDT

Ligand Pharmaceuticals Incorporated

555 Heritage Drive
Suite 200
Jupiter, FL 33458
United States
858 550 7500
https://www.ligand.com

版塊: Healthcare
行業: Biotechnology
全職員工: 58

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Matthew E. Korenberg	President & COO	831.77k	無	1975
Mr. Octavio Espinoza	Chief Financial Officer	613.59k	無	1971
Mr. Andrew T. Reardon J.D.	Chief Legal Officer & Secretary	614.87k	無	1975
Mr. Scott M. Plesha	Chief Executive Officer	無	無	1965
Mr. Paul J. Hadden	Senior Vice President of Investments & Business Development	無	無	無
Simon Latimer	Head of Investor Relations	無	無	無
Mr. Todd Pettingill	Director of Corporate Development	無	無	無
Ms. Audrey Warfield-Graham	Chief People Officer	無	無	無
Dr. Keith Marschke	Senior Vice President of Biology & Scientific Affairs	無	無	無
Dr. Vincent D. Antle	Senior Vice President of Technical Operations & QA - Capitsol	無	無	1969

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

公司管治

截至 2024年5月1日 止，Ligand Pharmaceuticals Incorporated 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：8；董事會：5；股東權利：5；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。